RT Journal Article
A1 Harris, Emily
T1 Safety Concerns Put a Stop to Maternal RSV Vaccine Study
JF JAMA
JO JAMA
YR 2024
DO 10.1001/jama.2024.5155
VO 331
IS 17
SP 1439
OP 1439
SN 0098-7484
AB A vaccine given during pregnancy that prevents respiratory syncytial virus (RSV) in infants was about 66% effective at protecting against RSV-associated respiratory illness, and about 69% effective at protecting against severe disease, according to a study in the New England Journal of Medicine. The data came from a randomized clinical trial involving more than 5000 pregnant people and their infants in 24 countries.However, the researchers stopped the trial early because of an increased risk of preterm births. About 7% of infants whose birthing parent had received the vaccine were born before 37 weeks compared with roughly 5% of infants whose birthing parent had received a placebo. The higher rate of preterm births was “predominantly observed” among low- and middle-income countries between August and December 2021, and was not explained by SARS-CoV-2 infection or COVID-19 vaccination, the researchers noted.
RD 5/20/2024
UL https://doi.org/10.1001/jama.2024.5155